• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Verona Pharma plc

    4/29/25 4:21:40 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VRNA alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001337845
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Verona Pharma plc
    SEC File Number
    001-38067
    Address of Issuer
    3 MORE LONDON RIVERSIDE
    London
    UNITED KINGDOM
    SE12RE
    Phone
    442032834200
    Name of Person for Whose Account the Securities are To Be Sold
    VIKAS SINHA
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    200001376600.008513200304/29/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common04/29/2025Exercise of Stock OptionsIssuerCheckbox not checked2000004/29/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    04/29/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    11/06/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Vikas Sinha

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $VRNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VRNA

    DatePrice TargetRatingAnalyst
    4/28/2025$100.00Buy
    TD Cowen
    4/21/2025$80.00Overweight
    Cantor Fitzgerald
    1/10/2025$68.00Buy
    ROTH MKM
    10/3/2024$50.00Overweight
    Wells Fargo
    5/22/2023$35.00 → $38.00Buy
    Jefferies
    9/19/2022$27.00Outperform
    Wedbush
    8/26/2022$31.00Overweight
    Piper Sandler
    11/12/2021$18.00 → $23.00Buy
    Canaccord Genuity
    More analyst ratings

    $VRNA
    SEC Filings

    See more
    • SEC Form 144 filed by Verona Pharma plc

      144 - Verona Pharma plc (0001657312) (Subject)

      5/27/25 4:33:47 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Verona Pharma plc

      144 - Verona Pharma plc (0001657312) (Subject)

      5/27/25 4:31:13 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Verona Pharma plc

      144 - Verona Pharma plc (0001657312) (Subject)

      5/20/25 4:30:55 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Verona Pharma Announces June 2025 Investor Conference Participation

      LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that senior management will participate in fireside chats at the following conferences in June 2025: Jefferies Global Healthcare ConferenceDate: Wednesday, June 4, 2025Time: 11:05 a.m. ET / 4:05 p.m. BSTLocation: New York, NY Goldman Sachs 46th Annual Global Healthcare ConferenceDate: Monday, June 9, 2025Time: 2:40 p.m. ET / 7:40 p.m. BSTLocation: Miami, FL A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company's website, www.veronapharma.com. For further information please

      5/21/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025

      Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces ten posters including seven additional analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease ("COPD"), two from nonclinical studies, and one from a real-world data analysis, will be presented at the American Thoracic Society Conference ("ATS") 2025. The posters are published on the ATS website an

      5/6/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2025, and provides a corporate update. "The remarkably strong US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonar

      4/29/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Financials

    Live finance-specific insights

    See more
    • Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2025, and provides a corporate update. "The remarkably strong US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonar

      4/29/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update

      LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-800-715-9871 for callers in the United States+1-646-307-1963 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Comp

      4/15/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025 Phase 2 programs in bronchiectasis and fixed-dose combination in COPD advance Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2024, and provide

      2/27/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Verona Pharma with a new price target

      TD Cowen initiated coverage of Verona Pharma with a rating of Buy and set a new price target of $100.00

      4/28/25 8:38:21 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Verona Pharma with a new price target

      Cantor Fitzgerald initiated coverage of Verona Pharma with a rating of Overweight and set a new price target of $80.00

      4/21/25 8:39:43 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH MKM initiated coverage on Verona Pharma with a new price target

      ROTH MKM initiated coverage of Verona Pharma with a rating of Buy and set a new price target of $68.00

      1/10/25 8:44:57 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

      SC 13G/A - Verona Pharma plc (0001657312) (Subject)

      11/14/24 5:46:11 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

      SC 13G/A - Verona Pharma plc (0001657312) (Subject)

      11/14/24 4:50:28 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Verona Pharma plc

      SC 13G - Verona Pharma plc (0001657312) (Subject)

      11/14/24 4:31:56 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

      Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

      10/8/24 5:00:00 AM ET
      $ENTO
      $OCS
      $ONCO
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update

      ENHANCE Phase 3 program enrollment continues on track to complete in 2H21 Board strengthened with NED appointment of Lisa Deschamps Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended March 31, 2021, and provides a corporate update. "The first quarter of 2021 set a positive tone for what we expect to be another exciting year of substantial progress for Verona Pharma," said David Zaccardelli, Pharm. D., President and Chief E

      4/29/21 2:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $VRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Hahn Mark W sold $3,733,944 worth of Ordinary Shares (400,000 units at $9.33), decreasing direct ownership by 3% to 12,678,992 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      5/29/25 4:16:57 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Zaccardelli David sold $3,734,579 worth of Ordinary Shares (400,000 units at $9.34), decreasing direct ownership by 3% to 13,590,168 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      5/29/25 4:15:16 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sinha Vikas exercised 160,000 units of Ordinary Shares at a strike of $0.50 and sold $1,502,928 worth of Ordinary Shares (160,000 units at $9.39) (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      5/22/25 4:06:12 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ebsworth David R bought $88,800 worth of Ordinary Shares (20,000 units at $4.44), increasing direct ownership by 2% to 940,003 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      11/18/24 4:20:05 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ebsworth David R bought $188,881 worth of Ordinary Shares (39,360 units at $4.80), increasing direct ownership by 4% to 920,003 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      11/7/24 6:57:21 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ackermann Christina bought $198,386 worth of Ordinary Shares (41,880 units at $4.74) (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      11/7/24 6:56:12 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care